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Targeting the differential addiction to anti-apoptotic
BCL-2 family for cancer therapy
Akane Inoue-Yamauchi1,w, Paul S. Jeng1, Kwanghee Kim2, Hui-Chen Chen1, Song Han1, Yogesh Tengarai Ganesan1,
Kota Ishizawa1, Sylvia Jebiwott2, Yiyu Dong1, Maria C. Pietanza3,4, Matthew D. Hellmann3,4, Mark G. Kris3,4,
James J. Hsieh5 & Emily H. Cheng1,6,7
BCL-2 family proteins are central regulators of mitochondrial apoptosis and validated anti-
cancer targets. Using small cell lung cancer (SCLC) as a model, we demonstrated the presence
of differential addiction of cancer cells to anti-apoptotic BCL-2, BCL-XL or MCL-1, which cor-
related with the respective protein expression ratio. ABT-263 (navitoclax), a BCL-2/BCL-XL
inhibitor, prevented BCL-XL from sequestering activator BH3-only molecules (BH3s) and BAX
but not BAK. Consequently, ABT-263 failed to kill BCL-XL-addicted cells with low activator BH3s
and BCL-XL overabundance conferred resistance to ABT-263. High-throughput screening
identiﬁed anthracyclines including doxorubicin and CDK9 inhibitors including dinaciclib that
synergized with ABT-263 through downregulation of MCL-1. As doxorubicin and dinaciclib also
reduced BCL-XL, the combinations of BCL-2 inhibitor ABT-199 (venetoclax) with doxorubicin or
dinaciclib provided effective therapeutic strategies for SCLC. Altogether, our study highlights
the need for mechanism-guided targeting of anti-apoptotic BCL-2 proteins to effectively acti-
vate the mitochondrial cell death programme to kill cancer cells.
DOI: 10.1038/ncomms16078 OPEN
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T
he BCL-2 family proteins dictate cellular survival or death
decisions by regulating the integrity of the mitochondrial
outer membrane (MOM)1. Apoptotic signals culminate in
MOM permeabilization (MOMP), prompting the release of
cytochrome c and the activation of caspases. Initiation of the
BCL-2 regulated cell death cascade occurs through the
transcriptional and posttranslational activation of proapoptotic
BH3-only molecules (BH3s), which serve as death sentinels that
either directly activate multidomain proapoptotic BAX and BAK
(‘activator’ BH3s) or inactivate multidomain anti-apoptotic BCL-
2, BCL-XL and MCL-1 (‘inactivator’ BH3s)2–6. BAX and BAK, the
essential effectors of MOMP, undergo stepwise, bimodal
conformational changes upon activation by the activator BH3s
to form homo-oligomers that mediate cytochrome c efﬂux4,6,7.
Conversely, anti-apoptotic BCL-2, BCL-XL and MCL-1 preserve
mitochondrial integrity through sequestration of activator BH3s
or partially activated, BH3-exposed, BAX/BAK monomers to
prevent the homo-oligomerization of BAX/BAK1–4,6,8. To evade
apoptotic checkpoints, cancer cells often overexpress anti-
apoptotic BCL-2 proteins9. Consequently, along with the fact
that activation of the BCL-2-controlled apoptotic pathway seems
critical for the efﬁcacy of most chemotherapeutics, BCL-2 family
members have emerged as attractive targets for therapeutic
development.
Structure-based efforts led to the development of the ﬁrst
speciﬁc small molecule inhibitor of the BCL-2 family, ABT-737
and its orally bioavailable analog ABT-263 (navitoclax) that bind
and inhibit BCL-2, BCL-XL and BCL-W, but not MCL-1 or
BCL2A1 (refs 10–14). Although navitoclax showed promising
clinical activity, it induced a dose-dependent thrombocytopenia
as an on-target result of BCL-XL inhibition15,16. This spurred the
development of ABT-199 (venetoclax or GDC-0199), a platelet-
sparing, selective BCL-2 inhibitor17. Venetoclax has exhibited
remarkable therapeutic efﬁcacy for relapsed/refractory chronic
lymphocytic leukaemia with an overall response rate of 79%
(ref. 18), resulting in its approval by the Food and Drug
Administration (FDA) for the treatment of chronic lymphocytic
leukaemia patients with 17p deletion. Selective inhibitors for
BCL-XL with robust preclinical activity have also been
generated19, but similar efforts to target MCL-1 have been less
successful. The lack of effective MCL-1 inhibitors positions MCL-
1 as a key primary as well as secondary resistance factor to ABT-
263 and ABT-199.
Small cell lung cancer (SCLC) is an aggressive type of
neuroendocrine carcinoma that represents 10–15% of all lung
cancer malignancies20. Standard ﬁrst-line treatment consists of a
combined regimen of platinum-based chemotherapy with
etoposide and typically elicits high initial response rates,
followed by almost universal disease recurrence and
progression21. As a result, 5-year survival rate is dismal (B5%)
with little improvement over the past 30 years20,21. Unlike non-
SCLC, which is commonly associated with targetable kinase
mutations, SCLC biology is less evidently tractable, driven instead
by nearly uniform loss of tumour suppressors TP53 and RB1
(refs 22,23). Preclinical studies showed that SCLC cell lines are
among the most sensitive tumour types to ABT-737 and ABT-263
(refs 10,11,24,25), suggesting that targeting the BCL-2 family
proteins may be a paradigm shifting therapeutic strategy for this
cancer. However, not all SCLC cell lines are sensitive to ABT-263
(refs 11,24,25) and limited single agent activity of navitoclax was
observed in a phase II trial for SCLC16. It has become evident that
combination therapy with ABT-263 is required to improve the
therapeutic outcome of SCLC. However, it remains unclear how
ABT-263 can be integrated with existing chemotherapeutics into
rational combination treatments for SCLC, or if particular classes
of targeted therapeutics will synergize favourably with ABT-263.
Moreover, reliable biomarkers for identifying patient populations
who will respond to ABT-263 monotherapy are yet unknown.
Using an unbiased high-throughput screening (HTS) strategy,
we identiﬁed anthracyclines including doxorubicin and CDK9
inhibitors including dinaciclib that enhanced the proapoptotic
effect of ABT-737/263 through downregulation of MCL-1. Both
doxorubicin and dinaciclib also cooperated with ABT-199 to
induce robust apoptosis, because they also partially reduced
BCL-XL. The in vivo therapeutic efﬁcacy of these combinations
was demonstrated in mouse xenograft models, validating new
potential therapeutic strategies for SCLC. Interestingly, we found
that some SCLC cell lines displayed differential addiction to
BCL-2, BCL-XL or MCL-1 for survival, which could be
determined by the respective protein expression ratio. Surpris-
ingly, ABT-263 failed to kill BCL-XL-addicted cells with low
expression of activator BH3s, as ABT-263 failed to prevent BCL-
XL from sequestering BAK in these cells. Consequently, over-
expression of BCL-XL conferred resistance to ABT-263, repre-
senting a previously unknown therapeutic limitation. Together,
our data establish a predictive paradigm for determining SCLC
addiction to anti-apoptotic BCL-2 family members and highlight
the need for mechanism-guided targeting of anti-apoptotic BCL-2
proteins for effective apoptosis induction.
Results
HTS identiﬁes anthracyclines that cooperate with ABT-263. To
improve the therapeutic outcome of ABT-263 for SCLC, we
sought to identify the best combination strategies that enhance
the proapoptotic effect of ABT-737/263. HTS of FDA-approved
anti-cancer agents was performed to identify agents that coop-
erate with ABT-737 to kill ABT-737-resistant SCLC. As repor-
ted10, DMS53 was sensitive whereas H196 was resistant to ABT-
737 (Fig. 1a). Interestingly, H196 was also resistant to the
chemotherapeutic agents used to treat SCLC (Fig. 1a). To explore
the mechanisms underlying the differential responses of H196
versus DMS53, the levels of BCL-2 family proteins were assessed.
The high expression of MCL-1 and low expression of BCL-2 in
H196 cells were probably accountable for their resistance to ABT-
737 (Fig. 1b). Supporting this notion, knockdown of MCL-1
sensitized H196 cells to ABT-737 (Supplementary Fig. 1). In
addition, H196 expressed lower levels of BID, BIM and PUMA
than DMS53 (Fig. 1b), which might contribute to their resistance
to ABT-737 and chemotherapeutic agents as reported5.
We next performed HTS of 76 FDA-approved anti-cancer
agents to identify agents that cooperate with ABT-737 to kill
H196 cells (Fig. 1c and Supplementary Data 1). Effector
concentration for half-maximum responses (EC50) of each
compound from the FDA panel with or without ABT-737 was
determined in H196 cells. Nine compounds from the FDA panel
were synergistic with ABT-737, resulting in a greater than twofold
decrease of EC50 (Fig. 1d). Five of the nine hits were
anthracyclines including doxorubicin (Fig. 1d). As doxorubicin
has been included in chemotherapeutic regimens for SCLC21, we
subsequently focused on doxorubicin. The combination of ABT-
737 and doxorubicin indeed induced robust apoptosis in H196
cells (Fig. 1e). In contrast, other chemotherapeutic agents used in
treating SCLC, including etoposide, cisplatin and camptothecin,
failed to induce comparable apoptosis as doxorubicin when
combined with ABT-737 (Fig. 1e). These data strongly argue that
ABT-737 does not simply lower the apoptotic threshold of
standard cytotoxic agents. In fact, only doxorubicin reduced
MCL-1 expression (Fig. 1f), which would sensitize H196 cells to
ABT-737 based on the MCL-1 knockdown experiments
(Supplementary Fig. 1).
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Figure 1 | HTS of FDA-approved anti-cancer agents identiﬁes anthracyclines that enhance the proapoptotic effect of ABT-737. (a) DMS53 and H196
cells were treated with the indicated agents for 48 h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (b) The expression of BCL-2
family proteins in DMS53 and H196 cells was assessed by immunoblot analysis. (c) A schematic of HTS to identify FDA-approved anti-cancer agents that
cooperate with ABT-737 to reduce the survival of H196 cells. H196 cells were treated with each compound at 12 two-fold serial dilution doses starting from
10±1mM ABT-737. Cell viability was assessed by Alamar Blue assays at 72 h and EC50 was calculated. (d) A summary of EC50s of anti-cancer
agents±ABT-737 in H196 cells. NA denotes ‘not applicable’, because the agent failed to achieve 100% growth inhibition at 10mM. (e) H196 cells were
treated with the indicated agents for 48 h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (f) H196 treated with the indicated agents
for 6 h were assessed by immunoblot analysis. (g) The mRNA levels of BCL-2 family in H196 cells treated with 2 mM doxorubicin for 3 h were assessed by
qRT–PCR. Data were normalized against b-Actin (mean±s.d., n¼ 2 independent experiments). (h) H196 cells treated with doxorubicin for the indicated
times were assessed by immunoblot analysis. (i) A summary of EC50s of ABT-263 in SCLC cell lines. The indicated SCLC cell lines were treated with
increasing concentrations of ABT-263. Cell viability was assessed by CellTiter-Glo assays at 48 h. DMS53 and H2171 cells were treated with 1 mM ABT-263
for 24 h and cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (j) The indicated SCLC cell lines were treated with 2 mM
doxorubicin±1mMABT-263 for 24 h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). *Po0.05 and ***Po0.001 (t-test). Unprocessed
original scans of blots are shown in Supplementary Fig. 11.
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Anthracyclines were reported to be global transcriptional
repressors that preferentially affect MCL-1 due to its short
messenger RNA half-life26. We conﬁrmed that doxorubicin
rapidly decreased MCL-1 mRNA in H196 cells (Fig. 1g and
Supplementary Fig. 2). Of note, doxorubicin did not further
reduce MCL-1 mRNA when combined with actinomycin D, a
general transcription inhibitor (Supplementary Fig. 2).
Doxorubicin also decreased BCL-2 and BCL-XL mRNA but to a
lesser extent. Only MCL-1 protein was greatly reduced within 6 h
of doxorubicin treatment, likely to be due to the highly labile
nature of MCL-1 protein (Fig. 1h). We subsequently assessed a
series of SCLC cell lines for their EC50 to ABT-263 (Fig. 1i).
H2171 and DMS53 displayed submicromolar EC50 to ABT-263
and were effectively killed by ABT-263 (Fig. 1i). In contrast,
H196, SW1271, H82, DMS114 and H446 were relatively resistant
to ABT-263. Importantly, the combination of ABT-263 and
doxorubicin induced robust apoptosis in these cell lines (Fig. 1j).
In summary, our HTS of the FDA-approved anti-cancer agents
identiﬁed anthracyclines including doxorubicin as a universal
combination strategy with ABT-263 in SCLC.
HTS identiﬁes CDK9 inhibitors that cooperate with ABT-263.
Although several targeted therapeutic agents have been demon-
strated to enhance the therapeutic effect of ABT-737/263 in
preclinical studies, an unbiased approach to identify the best
combination strategy for speciﬁc cancer types has not been
pursued. Accordingly, we extended our HTS to a pathway inhi-
bitor library that is composed of a diverse collection of 993 small
molecules against over 200 targets in more than 20 signalling
pathways (Supplementary Data 2). H196 cells were treated with
each compound from this library with or without ABT-737
(Fig. 2a). Scatterplot analysis of the average percentage growth
inhibition identiﬁed 11 compounds that conferred more inhibi-
tion when combined with ABT-737 (Fig. 2b). Of the 11 hit
compounds, 5 were cycline-dependent kinase (CDK) inhibitors
that share the common targets of CDK2 and CDK9 (Fig. 2c).
PHA-793887 (ref. 27), a CDK inhibitor that mainly targets
CDK2, was present in the library but was not identiﬁed as a hit.
Together, these data suggest that CDK9 is most probably the
shared target, which is further supported by the observation that
knockdown of CDK9 sensitized H196 cells to ABT-263 (Fig. 2d).
CDK9 is a serine-threonine kinase that forms the catalytic core
of p-TEFb complex and, in the presence of cyclin T,
phosphorylates Ser2 in the carboxy-terminal domain of RNA
polymerase II (Pol II) to stimulate transcription elongation28,29.
CDK9 inhibitors block transcription elongation and preferentially
downregulate transcripts with short half-life such as MCL-1
mRNA30,31. Indeed, knockdown of CDK9 reduced MCL-1 in
H196 (Fig. 2d). We conﬁrmed that dinaciclib, SNS-032 and
AZD5438 reduced the Ser2 phosphorylation of Pol II and
synergized with ABT-263 to kill H196 cells (Fig. 2e,f). We
subsequently focused on dinaciclib because it is more advanced in
clinical development32. Dinaciclib rapidly reduced MCL-1 mRNA
and protein (Fig. 2g,h). The synergistic effect of ABT-263 and
dinaciclib in triggering apoptosis was shown in all tested ABT-
263-resistant SCLC cell lines (Fig. 2i). Of note, PHA-793887
neither suppressed the Ser2 phosphorylation of Pol II nor
reduced MCL-1 (Supplementary Fig. 3).
Our HTS identiﬁed anthracyclines and CDK9 inhibitors as two
combination strategies with ABT-263 through downregulation of
MCL-1. Notably, overexpression of MCL-1 protected H196 cells
from apoptosis induced by combined ABT-263 and dinaciclib or
doxorubicin (Supplementary Fig. 4), supporting that down-
regulation of MCL-1 is responsible for the observed synergistic
proapoptotic effect. Notably, although410 different mammalian
target of rapamycin (mTOR) inhibitors were present in our
library, none were identiﬁed as hits. As it was reported that
mTOR inhibitors, including rapamycin and AZD8055, sensitize
SCLC cell lines to ABT-737/263 (refs 25,33), we compared the
death inducing activity of combined ABT-263 and mTOR
inhibitors with that of combined ABT-263 and dinaciclib in
four ABT-263-resistant SCLC cell lines (Supplementary Fig. 5).
Indeed, combined ABT-263 with dinaciclib was more potent in
triggering apoptosis than combined ABT-263 with mTOR
inhibitors (Supplementary Fig. 5).
Prediction of cellular addiction to anti-apoptotic BCL-2s. The
ﬁndings that doxorubicin and dinaciclib downregulated MCL-1
and induced apoptosis in H82 and DMS114 as single agents
raise the possibility that these cell lines might be dependent on
MCL-1 for survival (Figs 1j and 2i). In contrast, DMS53 and
H2171 might be dependent on BCL-2 and/or BCL-XL for sur-
vival given their sensitivity to ABT-263 (Fig. 1i). DMS114 is
unique among the studied SCLC cell lines in that it harbors
MCL1 ampliﬁcation. We hypothesized that a given SCLC cell
line might be addicted to a speciﬁc anti-apoptotic BCL-2
member for survival if it predominantly expresses that speciﬁc
anti-apoptotic BCL-2 member. Conversely, a given SCLC cell
line that does not predominantly express a speciﬁc anti-apop-
totic BCL-2 member might not be addicted to any single anti-
apoptotic BCL-2 member. To test this hypothesis, we ﬁrst
determined whether the seven SCLC cell lines display differ-
ential addiction to BCL-2, BCL-XL or MCL-1 for survival using
RNA interference (RNAi). Knockdown of MCL-1 but not BCL-
2 or BCL-XL induced signiﬁcant apoptosis in H82 and DMS114
(Fig. 3a and Supplementary Fig. 6), supporting that both cell
lines are addicted to MCL-1 for survival. In contrast, knock-
down of BCL-2 alone was sufﬁcient to induce signiﬁcant
apoptosis in DMS53 cell line (Fig. 3a and Supplementary
Fig. 6), supporting that DMS53 is addicted to BCL-2 for sur-
vival. Consistently, ABT-199 effectively killed DMS53 cells
(Supplementary Fig. 7). Analogously, H2171 and SW1271 were
probably addicted to BCL-XL for survival, because knockdown
of BCL-XL alone was sufﬁcient to induce signiﬁcant apoptosis
(Fig. 3a and Supplementary Fig. 6). Knockdown of BCL-2, BCL-
XL or MCL-1 failed to induce signiﬁcant apoptosis in H196 and
H446, suggesting that these cell lines are not addicted to any
single anti-apoptotic BCL-2 member for survival (Fig. 3a and
Supplementary Fig. 6). Notably, knockdown of both BCL-XL
and MCL-1 induced robust apoptosis in H196 (Supplementary
Fig. 8), which is consistent with its low expression of BCL-2
(Fig. 1b). To this end, we could divide these seven SCLC cell
lines into BCL-2-addicted, BCL-XL-addicted, MCL-1-addicted
or non-addicted to any single anti-apoptotic BCL-2 member
(Fig. 3a).
We next tested whether selective addiction to BCL-2, BCL-XL
or MCL-1 for survival is due to the predominant expression of
BCL-2, BCL-XL or MCL-1 in a given SCLC cell line by assessing
the expression of BCL-2 family proteins (Fig. 3b). The expression
of BCL-2, BCL-XL or MCL-1 was normalized against a-Tubulin
and the ratio of an individual anti-apoptotic BCL-2 member to all
three members was obtained. We found that the ratio of BCL-2 to
combined BCL-2, BCL-XL and MCL-1 was highest in BCL-2-
addicted DMS53, the ratio of BCL-XL was highest in BCL-XL-
addicted SW1271 and H2171, and the ratio of MCL-1 was highest
in MCL-1-addicted H82 and DMS114 (Fig. 3c). We also
compared the mRNA ratios to the protein ratios and found that
the mRNA ratios were less predictive than the protein ratios likely
due to dysregulated MCL-1 degradation in some cell lines
(Supplementary Fig. 9).
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Figure 2 | HTS of a small molecule pathway inhibitor library identiﬁes CDK9 inhibitors that enhance the proapoptotic effect of ABT-737. (a) A
schematic of HTS of the pathway inhibitor library to identify agents that cooperate with ABT-737 to kill H196 cells. H196 cells were used to screen the pathway
inhibitor library at 2mM±1mM ABT-737. Compounds were screened in duplicate and cell viability was assessed by Alamar Blue assays at 72h.
(b) Scatter plot analysis of the average percentage growth inhibition of each compound screened in H196 cells. The compounds that induced r50% growth
inhibition in the absence of ABT-737 while Z50% inhibition in the presence of ABT-737 were identiﬁed as positive hits (red dots). (c) A summary of hit
compounds identiﬁed by the HTS of the pathway inhibitor library. (d) H196 cells, transfected with scrambled siRNA (siSCR) or siRNA against CDK9, were
treated with 1mM ABT-263 and subjected to cell death or immunoblot analysis. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (e) H196
cells, treated with the indicated agents for 3 h, were assessed by immunoblot analysis. (f) H196 cells were treated with the indicated agents±1mMABT-737 for
24h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (g) The mRNA levels of BCL-2 family in H196 cells treated with 10 nM dinaciclib for
3 h were assessed by qRT-PCR. Data were normalized against b-Actin (mean±s.d., n¼ 2 independent experiments). (h) H196 cells, untreated or treated with
the indicated CDK9 inhibitors for 6h, were assessed by immunoblot analysis. (i) The indicated SCLC cell lines were treated with vehicle or dinaciclib (10nM for
H196, H82, and H446, or 20nM for SW1271 and DMS114) in the absence or presence of 1mM ABT-263 for 24h. Cell death was quantiﬁed by annexin-V
staining (mean±s.d., n¼ 3). **Po0.01 and ***Po0.001 (t-test). Unprocessed original scans of blots are shown in Supplementary Fig. 11.
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ABT-263 fails to kill BCL-XL-addicted cells with low BH3s. We
have demonstrated that both SW1271 and H2171 were dependent
on BCL-XL for survival based on the RNAi results (Fig. 3a).
However, SW1271 displayed the highest EC50 to ABT-263
whereas H2171 showed submicromolar EC50 to ABT-263
(Fig. 1i). To validate these results, viability was determined by
annexin-V staining and ABT-199 was included as a control.
ABT-263 but not ABT-199 induced robust apoptosis in H2171
(Fig. 4a). In contrast, ABT-263 only induced mild apoptosis in
SW1271. The dependency of SW1271 on BCL-XL for survival was
validated using a second small interfering RNA (siRNA) against
BCL-XL (Supplementary Fig. 10). Notably, lower expression of
BIM and BID was observed in SW1271 cells than in H2171 cells
(Fig. 3b). We have previously demonstrated that BID/BIM/
PUMA is required for ABT-737/263 to induce apoptosis because
ABT-737/263 displaces BID/BIM/PUMA from BCL-2/BCL-XL to
activate BAX/BAK indirectly5. Moreover, it was reported that
BIM expression levels predict the sensitivity of cancer cells to
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Figure 3 | The SCLC cell lines display differential addiction to anti-apoptotic BCL-2 family proteins for survival. (a) The indicated SCLC cell lines were
transfected with scrambled siRNA (siSCR) or siRNA against BCL-2, BCL-XL, or MCL-1. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3).
(b) The expression of BCL-2 family proteins in the indicated SCLC cell lines was assessed by immunoblot analysis using the indicated antibodies. (c) The
protein expression ratios of BCL-2, BCL-XL, or MCL-1 to combined BCL-2, BCL-XL and MCL-1 in the indicated SCLC cell lines. The expression of BCL-2, BCL-
XL, or MCL-1 was normalized against a-Tubulin and the ratio of an individual anti-apoptotic BCL-2 member to all three members was obtained based on two
representative immunoblot analyses. Arrows indicate the cell lines that display addiction to BCL-2, BCL-XL or MCL-1 for survival. *Po0.05, **Po0.01 and
***Po0.001 (Student’s t-test). Unprocessed original scans of blots are shown in Supplementary Fig. 11.
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ABT-263 (ref. 25). To determine whether the differential
sensitivities of these two cell lines to ABT-263 is caused by
different BIM expression, BIM was silenced in H2171. Indeed,
knockdown of BIM conferred resistance to ABT-263 in H2171
(Fig. 4b).
To further conﬁrm that activator BH3s are required for ABT-
263 to induce apoptosis, we employed activator BH3-deﬁcient
Bid /Bim /Puma /Noxa / quadruple knockout
(QKO) mouse embryonic ﬁbroblasts (MEFs)6. Knockdown of
Mcl-1 sensitized wild-type MEFs to ABT-263- but not ABT-
199-induced apoptosis (Fig. 4c). However, ABT-263 failed to
kill QKO cells with Mcl-1 knockdown (Fig. 4c). This is in stark
contrast to our reported knockdown experiments showing that
concurrent KD of Bcl-2, Bcl-xL and Mcl-1 is sufﬁcient to induce
autoactivation of BAX/BAK and apoptosis in QKO cells6. These
data raise a testable hypothesis that ABT-263 may be unable to
disrupt the BCL-XL/BAK or BCL-XL/BAX interaction and
thereby fails to kill QKO cells with Mcl-1 knockdown. To
examine this hypothesis, co-immunoprecipitation was
performed. In wild-type MEFs, ABT-263 was able to reduce
the interaction between BCL-XL and BAX, BAK or BIM
(Fig. 4d). In contrast, ABT-263 failed to disrupt the
interaction between BCL-XL and BAK in QKO cells, whereas
it partially reduced the interaction between BCL-XL and BAX
(Fig. 4d). Of note, ABT-263 was able to reduce the interaction
between BCL-2 and BAX or BIM in both wild-type and QKO
cells (Fig. 4d). As reported6,34,35, BCL-2 only interacted with
BAX but not BAK. Together, these data suggest that ABT-263
releases BIM and other activator BH3s from BCL-2 and BCL-XL
to disrupt the BCL-XL/BAK interaction indirectly. Accordingly,
we examined whether ABT-263 has differential effects on
disrupting the BCL-XL/BAK interaction in H2171 versus
SW1271 cells. ABT-263 had minimal effect on the interaction
between BCL-XL and BAK in SW1271 with low BIM
expression, whereas ABT-263 greatly reduced this interaction
in H2171 with high BIM expression (Fig. 4e). This is consistent
with the notion that BIM is required to disrupt the BCL-XL/
BAK interaction after its displacement from BCL-XL or BCL-2
by ABT-263. Collectively, ABT-263 is likely a poor
BCL-XL inhibitor in cells with low activator BH3s because it
is unable to directly disrupt the BCL-XL/BAK interaction.
Overexpression of BCL-XL confers resistance to ABT-263. We
have reported that BCL-2, BCL-XL and MCL-1 inhibit bimodal
activation of BAX/BAK by sequestering activator BH3s and ‘BH3-
exposed’ BAX/BAK monomers, respectively6. BCL-XL is superior
to BCL-2 in preventing apoptosis, because BCL-XL but not BCL-2
can bind and inhibit BAK6. Given that ABT-263 could not
directly disrupt the BCL-XL/BAK interaction, we hypothesized
that overexpression of BCL-XL might provide more resistance to
ABT-263 than overexpression of BCL-2 based on the unique
capacity of BCL-XL to directly bind and inhibit ‘BH3-exposed’
BAK monomers. Indeed, overexpression of HA-tagged BCL-XL
but not BCL-2 inhibited ABT-263-induced apoptosis in BCL-XL-
addicted H2171 (Fig. 4f). Notably, the BCL-XL BH1 mutant
(G138E/R139L/I140N) that is unable to sequester proapoptotic
BCL-2 members failed to protect H2171 (Fig. 4f). BCL-XL
overexpression resulted in a B24-fold increase in the EC50 of
ABT-263 whereas BCL-2 overexpression resulted in a B4-fold
increase in H2171 (Fig. 4f). Furthermore, overexpression of BCL-
XL in BCL-2-addicted DMS53 completely inhibited ABT-263-
induced apoptosis, whereas overexpression of BCL-2 only
partially inhibited apoptosis (Fig. 4g). BCL-XL overexpression
resulted in aB36-fold increase in the EC50 of ABT-263, whereas
BCL-2 overexpression resulted in a B6-fold increase in DMS53
(Fig. 4g). In both H2171 and DMS53, BCL-XL overexpression
increased the EC50 of ABT-263 by sixfold in comparison with
BCL-2 overexpression. Overall, these results suggest that
overexpression of BCL-XL might be a potential resistance
mechanism to ABT-263 due to the inability of ABT-263 to
disrupt the BCL-XL/BAK interaction.
JQ1 neither downregulatesMCL-1 nor cooperates with ABT-263.
BRD4, a member of the BET family, is involved in the control of
transcriptional elongation by Pol II through its recruitment of
p-TEFb. Hence, we examined whether the BET inhibitor JQ1 (ref.
36) could recapitulate the effect of CDK9 inhibitors. JQ1 had no
apparent single agent activity and failed to synergize with ABT-263
(Fig. 5a). Furthermore, there was no clear correlation of EC50s
between dinaciclib and JQ1 (Fig. 5b), for example, DMS114 was
sensitive to dinaciclib but not JQ1. Interestingly, three SCLC cell
lines with c-MYC ampliﬁcation, including H82, H2171 and H446,
had the lowest EC50 to dinaciclib, which is consistent with a recent
identiﬁcation of CDK9 inhibition as a therapeutic strategy for
c-MYC-overexpressing hepatocellular carcinoma37. c-MYC
expression was indeed higher in c-MYC-ampliﬁed SCLC cell lines
(Fig. 5c). As the EC50 was determined by growth inhibition, it
might reﬂect anti-proliferative rather than death-inducing activity.
Accordingly, cell death was quantiﬁed by annexin-V staining
(Fig. 5d). Potent induction of apoptosis by dinaciclib at both 10nM
(Fig. 2i) and 20nM (Fig. 5d) was observed in H82 and DMS114
cells that are addicted to MCL-1. In contrast, JQ1 failed to induce
apoptosis in both H82 and DMS114 (Fig. 5d). JQ1 only induced
marked apoptosis in H446 cells that are not addicted to any single
anti-apoptotic member (Fig. 5d). Signiﬁcant apoptosis was also
observed in H446 cells treated with 20nM but not 10nM dinaciclib
Figure 4 | ABT-263 fails to disrupt the interaction between BCL-XL and BAK in the absence of activator BH3s. (a) H2171 and SW1271 cells were treated
with vehicle, 1mM ABT-263 or 1mM ABT-199 for 48 h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (b) H2171 cells, transfected with
scrambled siRNA (siSCR) or siRNA against BIM, were untreated or treated with ABT-263 for 24 h. Cell death was quantiﬁed by annexin-V staining
(mean±s.d., n¼ 3). The expression of BIM was assessed by an anti-BIM immunoblot. (c) SV40-transformed wild-type or Bid /Bim /Puma /
Noxa / QKO MEFs, infected with retrovirus expressing shRNA against luciferase or Mcl-1, were untreated or treated with ABT-263 or ABT-199 for
24 h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). (d) SV40-transformed wild-type or Bid /Bim /Puma /Noxa / QKO
MEFs stably expressing GFP, HA-BCL-XL or HA-BCL-2, untreated or treated with ABT-263, were subjected to anti-HA immunoprecipitation. The input (5%)
and immunoprecipitates were assessed by immunoblot analysis. (e) H2171 and SW1271 cells, untreated or treated with ABT-263, were subjected to anti-
HA immunoprecipitation. The input (5%) and immunoprecipitates were assessed by immunoblot analysis. Arrow indicates a cross-reactive band.
(f) H2171 cells stably expressing GFP, HA-BCL-2, HA-BCL-XL, or HA-BCL-XL BH1 mutant were untreated or treated with 1 mM ABT-263 for 24 h. Cell death
was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). EC50 of ABT-263 in H2171 cells was assessed by CellTiter-Glo assays at 48 h. The expression of
HA-tagged BCL-2 and BCL-XL protein was assessed by immunoblot analysis. (g) DMS53 cells stably expressing GFP, HA-BCL-2, HA-BCL-XL or HA-BCL-XL
BH1 mutant were untreated or treated with 1 mM ABT-263 for 24 h. Cell death was quantiﬁed by annexin-V staining (mean±s.d., n¼ 3). EC50 of ABT-263
in H2171 cells was assessed by CellTiter-Glo assays at 48 h. The expression of HA-tagged BCL-2 and BCL-XL protein was assessed by immunoblot analysis.
***Po0.001 (Student’s t-test). Unprocessed original scans of blots are shown in Supplementary Fig. 11.
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(Figs 2i and 5d). Dinaciclib appeared to inhibit proliferation rather
than inducing apoptosis in another c-MYC-ampliﬁed H2171 cells
that are addicted to BCL-XL (Fig. 5b,d).
To this end, we envisioned that the reason why JQ1 fails to
synergize with ABT-263 is most likely due to its inability to
downregulate MCL-1. JQ1 was shown to prevent the binding of
Control 
ABT-263 
0 
20 
40 
60 
80 
100 
Control 
JQ-1 
Dinaciclib 
%
 D
ea
th
 
SW1271 
0 
20 
40 
60 
80 
100 
%
 D
ea
th
 
H82 
Control 
JQ-1 
Dinaciclib 
0 
20 
40 
60 
80 
100 
%
 D
ea
th
 
DMS114 
Control 
JQ-1 
Dinaciclib 
0 
20 
40 
60 
80 
100 
%
 D
ea
th
 
H196
Control 
JQ-1 
Dinaciclib 
a
c-MYC
DM
S1
14
H8
2
DM
S5
3
H1
96
H4
46
SW
127
1
H2
171
d
cb
Log10[JQ1] (μM)
%
 G
ro
wt
h 
in
hi
bi
tio
n
–2 –1 0 1
0
50
100
2
%
 G
ro
wt
h 
in
hi
bi
tio
n
Log10[Dinaciclib] (nM)
0
50
100
0 1 2 3
18.42DMS53
6.394H2171
ResistantSW1271
6.262H82
9.265DMS114
ResistantH196
7.29H446
EC50 (nM) 
EC50 (μM)
DMS53 0.2194
DMS114 >10
SW1271 >10
H82 0.8066
H196 >10
H2171 0.4342
H446 0.2989
0 
20 
40 
60 
80 
DMS53 
H2171 
SW1271 
H82 
DMS114 
H196 
H446 
%
 D
ea
th
 
Control 
Dinaciclib 
JQ1 
e
0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
1.4 
1.6 
MCL-1 BCL-XL c-MYC 
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
Control 
Dinaciclib 
JQ1 
Control 
JQ-1 
Dinaciclib 
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
H2171 
MCL-1 BCL-XL c-MYC 
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
0
H82
0 
MCL-1 BCL-XL c-MYC 
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6 H446 
BCL-XL
MCL-1
MYC
Tubulin
BCL-XL
MCL-1
MYC
Tubulin
BCL-XL
MCL-1
MYC
Tubulin
Control 
JQ-1 
Dinaciclib 
Control 
JQ-1 
Dinaciclib 
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BRD4 to super-enhancers and cause transcription elongation
defects that preferentially impact genes with super-enhancers,
such as c-MYC and BCL-XL38. We next examined the effect of
dinaciclib and JQ1 on the expression of c-MYC, MCL-1 and
BCL-XL in H82, H2171 and H446 cells (Fig. 5e). Dinaciclib
greatly reduced the expression of both MCL-1 and c-MYC in
these cell lines (Fig. 5e). In contrast, JQ1 induced MCL-1
(Fig. 5e), consistent with its inability to either kill MCL-1-
addicted cells or synergize with ABT-263. Intriguingly, c-MYC
was reduced, unaffected or induced by JQ1 in these cell lines
(Fig. 5e), which is similar to what has been reported for lung
adenocarcinoma39. The anti-proliferative effect of JQ1 for these
cell lines might be unrelated to c-MYC, as suggested for lung
adenocarcinoma39. Collectively, our data suggest that dinaciclib
will probably have single-agent anti-tumour activity against a
subset of SCLC that either carry c-MYC ampliﬁcation or are
MCL-1-addicted.
Effective combination strategies for SCLC using ABT-199.
Although doxorubicin and dinaciclib had more prompt and
profound effects on reducing the expression of MCL-1 than BCL-
2 and BCL-XL, we found that prolonged treatment of SCLC cells
with these agents also partially reduced BCL-XL (Fig. 6a). These
ﬁndings suggested a potentially effective therapeutic strategy in
which combined ABT-199 with doxorubicin or dinaciclib might
be sufﬁcient to trigger apoptosis in SCLC. To test this idea, we
ﬁrst assessed EC50 of ABT-199 in various SCLC cell lines
(Fig. 6b). Consistent with our characterization of DMS53 cells as
BCL-2-addicted, DMS53 had the lowest EC50 to ABT-199 and
was the only cell line that underwent potent apoptosis following
ABT-199 treatment (Fig. 6b). Importantly, combined ABT-199
with doxorubicin or dinaciclib induced robust apoptosis in all
tested SCLC cells including those ABT-263-resistant ones
(Fig. 6c,d).
We next examined the in vivo anti-tumour efﬁcacy of combined
ABT-199 and doxorubicin or dinaciclib in the H446 xenograft
model. Of note, H446 harbours mutations of RB1 and TP53 as well
as c-MYC ampliﬁcation, all of which are pathognomonic mutations
of SCLC. Consistent with our in vitro study (Fig. 6c), monotherapy
with ABT-199 or doxorubicin had minimal and modest effects on
tumour growth, respectively (Fig. 6e). Importantly, combined ABT-
199 with doxorubicin markedly inhibited tumour growth without
overt signs of toxicity (Fig. 6e). Similarly, combined ABT-199 with
dinaciclib was superior to the respective monotherapy and greatly
suppressed tumour growth (Fig. 6f). The therapeutic effects of
combined ABT-199 with doxorubicin or dinaciclib were further
demonstrated in a patient-derived SCLC xenograft (Fig. 6g,h).
Collectively, these data suggest that combined ABT-199 with
doxorubicin or dinaciclib could provide effective therapeutic
strategies for SCLC.
Discussion
Evading cell death is one of the hallmarks of cancer40. Oncogenic
transformation that drives uncontrolled cell-cycle progression
often activates innate tumour-suppressive checkpoints that
trigger apoptosis41. One plausible explanation is that BIM and
PUMA are transcriptionally activated by E2F1 (ref. 42), a key cell
cycle driver upon malignant transformation. To abrogate
apoptotic checkpoints, cancer cells often overexpress anti-
apoptotic BCL-2 family proteins that sequester upregulated
BIM and PUMA. Hence, many cancer cells are likely ‘primed’
to undergo apoptosis upon the administration of BAD and
NOXA mimetics that displace BIM/PUMA from BCL-2/BCL-XL
and MCL-1, respectively, to activate BAX/BAK12–14. As most
normal cells do not have excessive BIM/PUMA readily
complexed with anti-apoptotic BCL-2 members, they are less
‘primed’ and less susceptible to BAD or NOXA mimetics. In fact,
clinical efﬁcacy of ABT-263 (navitoclax) and ABT-199
(venetoclax) has been demonstrated in clinical trials12–14,18. In
the era of precision medicine, it is paramount to identify and
select patients who will respond to ABT-263 or ABT-199. Given
that clinically applicable MCL-1 inhibitors are not yet available,
strategies such as combination therapy to improve the therapeutic
efﬁcacy of ABT-263/199 are needed. Using protein expression
ratios, we were able to predict the dependency of SCLC cell lines
on BCL-2, BCL-XL or MCL-1 for survival. Moreover, we have
identiﬁed two combination strategies through unbiased HTS, that
is, combining ABT-263 with anthracyclines such as doxorubicin
or with CDK9 inhibitors such as dinaciclib, which induced potent
apoptosis in all examined SCLC cell lines regardless of their
dependency on different anti-apoptotic BCL-2 members for
survival (Fig. 7a). We further demonstrated that ABT-199 could
replace ABT-263 for these two combination strategies, because
both doxorubicin and dinaciclib also partially reduced BCL-XL
(Fig. 7a). The combination strategies using ABT-199 are expected
to reduce the toxicity associated with ABT-263.
Mechanistically, therapeutic modalities that either reduce
MCL-1 mRNA/protein or induce proapoptotic BCL-2 family
proteins could synergize with ABT-263 to induce apoptosis.
Examples include anthracyclines and CDK9 inhibitors that
downregulate MCL-1 (refs 26,30,31), histone deacetylase and
MEK inhibitors that induce BIM43–45, and phosphatidyl
inositol 3-kinase inhibitors that induce PUMA44. Cancer
type-speciﬁc synergizers of ABT-263 will probably prevail due
to differing aberrant signalling pathways that coalesce into
unique vulnerabilities. MEK and phosphatidyl inositol 3-kinase
inhibitors were not identiﬁed in our HTS of SCLC in which
kinase mutations are less common. Instead, anthracyclines and
CDK9 inhibitors with transcriptional repressor function
were identiﬁed as top hits in SCLC where near universal
inactivation of p53 and RB1 directly impacts the transcriptional
landscape.
Figure 6 | Doxorubicin or dinaciclib cooperates with ABT-199 to kill SCLC cells. (a) H196 cells, treated with dinaciclib or doxorubicin for 18 h, were
assessed by immunoblot analysis. (b) A summary of EC50s of ABT-199. Cell death response to 1 mM ABT-199 was quantiﬁed by annexin-V staining at 48 h
(mean±s.d., n¼ 3). (c) The indicated cell lines, treated with 2 mM doxorubicin±1 or 2mM ABT-199, were quantiﬁed by annexin-V staining at 24 h for
H2171 and H446 or at 48 h for H196 and SW1271 (mean±s.d., n¼ 3). (d) The indicated cell lines, treated with 10–20 nM dinaciclib±1 or 2 mM ABT-199,
were quantiﬁed by annexin-V staining at 24 h for H2171 and H446, at 48 h for H196, or at 72 h for SW1271 (mean±s.d., n¼ 3). *Po0.05, **Po0.01 and
***Po0.001 (Student’s t-test). (e) NSG mice bearing H446 xenografts were treated with vehicle (n¼ 6), ABT-199 (100mg kg 1, n¼ 8), doxorubicin
(2mg kg 1, n¼8), or combined ABT-199 and doxorubicin (n¼ 8). tumour volumes were measured twice weekly by caliper (mean±s.d.). *P¼0.0022 and
**Po0.0001 (two-way analysis of variance (ANOVA)). (f) NSG mice bearing H446 xenografts were treated with vehicle (n¼ 8), ABT-199 (100mg kg 1,
n¼ 8), dinaciclib (20mg kg 1, n¼8), or combined ABT-199 and dinaciclib (n¼ 8). *P¼0.0002; **P¼0.0034 (two-way ANOVA). (g) NSG mice bearing
patient-derived SCLC xenografts were treated with vehicle (n¼ 5), ABT-199 (100mg kg 1, n¼4), doxorubicin (2mg kg 1, n¼ 6), or combined ABT-199
and doxorubicin (n¼4). *P¼0.0029; **Po0.0001 (two-way ANOVA). (h) NSG mice bearing patient-derived SCLC xenografts were treated with vehicle
(n¼6), ABT-199 (100mg kg 1, n¼ 6), dinaciclib (30mg kg 1, n¼ 6), or combined ABT-199 and dinaciclib (n¼8). **Po0.0001 (two-way ANOVA).
Unprocessed original scans of blots are shown in Supplementary Fig. 11.
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It was reported that oncogenic and lineage-speciﬁc transcrip-
tion factors are associated with super-enhancers in SCLC46, and
that JQ1 preferentially inhibits the transcription of genes with
super-enhancers38, suggesting that JQ1 may provide a therapeutic
effect for SCLC. However, JQ1 neither downregulated MCL-1 nor
sensitized SCLC cell lines to ABT-263 and the EC50s of JQ1 did
not correlate with those of dinaciclib in the examined SCLC cell
lines. Interestingly, we found that SCLC cell lines with c-MYC
ampliﬁcation were more sensitive to dinaciclib and dinaciclib
alone was sufﬁcient to induce apoptosis in MCL-1-addicted SCLC
cell lines. Together, our data suggest that CDK9 inhibitors may
have single-agent anti-tumour activity against a subset of SCLC
that either carry c-MYC ampliﬁcation or are MCL-1-addicted. It
was reported that SCLC is highly sensitive to a covalent CDK7
inhibitor, THZ1 (ref. 46). During transcription initiation, the
carboxy-terminal domain of Pol II is phosphorylated on Ser5 by
the TFIIH-associated kinase CDK7, and as Pol II elongates, Ser2
is increasingly phosphorylated by CDK9/p-TEFb, while Ser5
phosphorylation is gradually removed by phosphatases29. In fact,
THZ1 was shown to reduce the phosphorylation of both Ser5 and
Ser2 in SCLC46. It is possible that downregulation of MCL-1 is
responsible for the death-inducing activity of THZ1 in SCLC.
Using RNAi to determine the dependency on individual anti-
apoptotic BCL-2 members for survival, we have classiﬁed SCLC
cell lines into BCL-2-addicted, BCL-XL-addicted, MCL-1-
addicted or non-addicted to any single anti-apoptotic BCL-2
member. As expected, the BCL-2-addicted SCLC cells were
sensitive to both ABT-199 and ABT-263, whereas the MCL-1-
addicted SCLC cells were insensitive to both. Surprisingly, the two
BCL-XL-addicted SCLC cell lines showed differential sensitivity to
ABT-263 due to different BIM expression. We have previously
established an interconnected hierarchical model that explains
how the intricate interplays between three BCL-2 subfamilies
dictate cellular survival versus death6 (Fig. 7b). Anti-
apoptotic BCL-2, BCL-XL and MCL-1 inhibit apoptosis through
sequestering activator BH3s from activating BAX/BAK, providing
a frontline protection against apoptotic insults2–4. In addition,
BCL-2, BCL-XL and MCL-1 can sequester partially activated,
BH3-exposed, BAX/BAK monomers to prevent the homo-
oligomerization of BAX/BAK (ref. 6), serving as a fail-safe
mechanism or the second line of defense. We showed that ABT-
263 prevented BCL-2 and BCL-XL from sequestering BIM and
BAX, but failed to directly disrupt the interaction of BCL-XL and
BAK (Figs 4 and 7b). The inability of ABT-263 to breach the
second-line defense of BCL-XL against BAK foretells major
limitations to its use. ABT-263 is probably ineffective in treating
BCL-XL-addicted cancers with low expression of activator BH3s
such as BIM, as well as cancers with BCL-XL overabundance,
which prevents the BH3-exposed BAK monomers from
undergoing homo-oligomerization (Fig. 7c). It is intriguing that
ABT-263 fails to directly dissociate the BCL-XL/BAK complexes
given the high binding afﬁnity of ABT-263 to the hydrophobic
dimerization groove of BCL-XL. BAX appears to differ from BAK
because ABT-263 could disrupt the interaction between BAX and
BCL-XL or BCL-2 (Figs 4 and 7b). It is possible that additional
contact sites between BCL-XL and BAK further strengthen the
BH3-in-groove heterodimers and/or prevent the accessibility of
ABT-263 to the dimerization pocket. Alternatively, the lipid
milieu of MOM where BCL-XL and BAK reside may modulate
their interaction. Nonetheless, targeting the interaction between
BCL-XL and BAK is essential for the treatment of ‘poorly primed’
yet BCL-XL-addicted cancer (Fig. 7c), which remains unaddressed
by ABT-263.
A potential limitation for our prediction model extends to
cancers with high expression of BCL2A1 or BCL-W. Notably,
SCLC has the lowest expression of BCL2A1 among the 1,000 cell
lines analysed by the Cancer Cell Line Encyclopedia project47.
The predominant association of a speciﬁc anti-apoptotic BCL-2
member with BIM and BAK has been shown to predict
dependency for survival in multiple myeloma and AML,
respectively48,49. Thus far, most of the prediction methods have
been focused on the identiﬁcation of ABT-263-responsive
cancers. BH3 proﬁling is one such example, which evaluates
apoptotic sensitivity or ‘mitochondrial priming’ of cancer cells by
measuring whether BH3 domain peptides induce MOMP50. Of
note, our prediction method may not be applicable to highly
primed cancer such as hematological malignancies that highly
express BIM as revealed by the Cancer Cell Line Encyclopedia
project. Highly primed cancers may be sensitive to the
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Figure 7 | Schematic depiction of mechanism-guided targeting of the
BCL-2 family for cancer therapy. (a) Differential targeted inhibition of BCL-
2, BCL-XL or MCL-1 by ABT-199, ABT-263, anthracyclines, or CDK9
inhibitors. (b) A schematic depicts the interconnected hierarchical model of
cell death regulation by the BCL-2 family proteins and differential inhibitory
activity of ABT-263 against BCL-2 versus BCL-XL. ABT-263 prevents BCL-2
and BCL-XL from sequestering both activator BH3s and BAX. In contrast,
ABT-263 fails to prevent BCL-XL from sequestering BAK. (c) BCL-XL
overabundance confers resistance to ABT-263 where BCL-XL prevents the
‘BH3-exposed’ BAK monomers from undergoing homo-oligomerization.
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knockdown of any individual anti-apoptotic BCL-2 member even
though they predominantly express one anti-apoptotic BCL-2
member. Accordingly, highly primed cancers may be sensitive to
ABT-263 even though they are MCL-1-dependent, which has
been shown in multiple myeloma48.
Our study establishes a framework for identifying and targeting
the differential addiction to anti-apoptotic BCL-2 family proteins
in SCLC, which could potentially be applied to other cancer types.
Combined inhibition of BCL-2, BCL-XL and MCL-1 through
mechanism-guided combination therapy will provide the most
effective and a potentially universal therapeutic strategy to
eradicate cancer cells through apoptotic induction. We presented
two such strategies, that is, the combinations of ABT-199 and
doxorubicin or dinaciclib. Furthermore, we have identiﬁed the
inability of ABT-263 to prevent BCL-XL from sequestering BAK
as a major limitation of its application in cancer therapy. A better
understanding of the BCL-XL/BAK interaction may aid in the
development of a better BCL-XL inhibitor, which is critical for the
advancement of targeted therapies against BCL-2 family, as is the
development of a clinically applicable MCL-1 inhibitor. Overall,
this study demonstrates the feasibility of exploiting the inter-
connected hierarchical cell death model for the development of
speciﬁc therapeutic strategies aimed at direct activation of
mitochondrial apoptosis in susceptible cancer cells.
Methods
Cell culture and viability assay. NCI-H196, SW1271, NCI-H2171, NCI-H446,
DMS53 and DMS114 were obtained from the American Type Culture Collection.
H82 was obtained from Dr Charles Rudin at Memorial Sloan Kettering Cancer
Center. All cell lines were cultured according to the recommendations of the
American Type Culture Collection. SV40-transformed wild-type or Bid /
Bim /Puma /Noxa / MEFs were described previously6. Cell death was
quantiﬁed by Annexin V (BioVison) staining, followed by ﬂow cytometric analyses
using an LSRFortessa (BD Biosciences). Data were analysed using FACSDiva (BD
Biosciences). For EC50 determination, cell viability was assessed by the CellTiter-
Glo luminescence assays (Promega) using 96-well plates and a luminescent plate
reader (SpectraMax M2e, Molecular Devices). EC50 value was calculated using
Prism software (GraphPad). P-values for statistical analyses were obtained with
Student’s t-test. The chemicals used are as follows: ABT-737 (Selleck Chemicals);
ABT-263 (AbbVie and Selleck Chemicals); ABT-199 (AbbVie and Selleck
Chemicals); dinaciclib (Selleck Chemicals); SNS-032 (Selleck Chemicals); AZD5438
(Selleck Chemicals); JQ1 (Selleck Chemicals); doxorubicin (Sigma); etoposide
(Sigma); cisplatin (Sigma); camptothecin (Sigma); rapamycin (Sigma); everolimus
(Selleck Chemicals); AZD8580 (Selleck Chemicals); FDA-panel for HTS (Sigma);
actinomycin D (Sigma); PHA-793887 (Selleck Chemicals); and pathway inhibitors
for HTS (Selleck Chemicals).
High-throughput screening. HTS was performed by the HTS Core Facility at
Memorial Sloan Kettering Cancer Center using an automated 384-well platform.
H196 cells were screened against FDA-approved anti-cancer agents (Sigma) and a
pathway inhibitor library (Selleck Chemicals) in combination with ABT-737. For
the screening of FDA panel, H196 cells were treated with each compound at 12
twofold serial dilution doses starting from 10 mM in the absence or presence of
1 mM ABT-737. Compounds were screened in duplicate and the growth inhibition
was assessed by Alamar Blue assays at 3 days post drug treatment. The average Z’
factor for the assay robustness was 0.45. Dose response curves for the FDA panel
were ﬁtted using logistic four-parameter sigmoid regression equations and EC50
values were calculated by Sigma-plot (Systat Software). For the screening of
pathway inhibitors, H196 cells were treated with each compound at 2 mM in the
absence or presence of 1 mM ABT-737. Compounds were screened in duplicate and
the growth inhibition was assessed by Alamar Blue assays at 3 days post drug
treatment. The average Z’ factor for the assay robustness was 0.48. Scatterplot
analysis of the average percentage growth inhibition was performed to identify
compounds that synergized with ABT-737 to kill H196 cells.
RNA interference. siRNA oligos were purchased from Ambion Silencer Select
oligos (Applied Biosystems), the sequences of which are summarized in
Supplementary Data 3. siRNA oligos were reverse transfected with Lipofectamine
RNAiMAX (Invitrogen) to a ﬁnal concentration of 10 nM.
Reverse transcription and quantitative PCR. Total RNA was extracted from cells
with TRIZOL (Life Technologies) according to the manufacturer’s instruction.
Reverse transcription was performed with oligo-dT plus random decamer primers
(Ambion) with SuperScript II (Life Technologies). The primers are summarized in
Supplementary Data 3. Quantitative PCR was performed with SYBR Green Master
Mix (Applied Biosystems) in duplicate with the indicated gene-speciﬁc primers.
Quantitative PCR was performed on an ABI Prism 7,300 sequence detection
system (Applied Biosystems). Data were analysed by normalization against b-actin.
Immunoblot analysis and immunoprecipitation. Cells were lysed in RIPA buffer.
Protein concentration was determined by BCA kit (Pierce). Twenty-ﬁve to 50 mg of
proteins were resolved by 10% NuPAGE (Life Technologies), transferred onto
polyvinylidene diﬂuoride membrane (Immobilon-P, Millipore). Antibody detection
was accomplished using enhanced chemiluminescence method (Western Light-
ning, PerkinElmer) and LAS-3000 Imaging system (FUJIFILM). Antibodies used
for immunoblot analysis are listed as followed: anti-BAK (NT, Millipore), anti-
BAX (N-20, Santa Cruz Biotechnology), anti-BIM (C34C5, Cell Signaling Tech-
nology), anti-PUMA (no. 4976, Cell Signaling Technology), anti-NOXA (ab13654,
Abcam), anti-BID (FL-195, Santa Cruz Biotechnology), anti-BCL-2 (6C8), anti-
BCL-XL (7B2.5), anti-MCL-1 (S-19, Santa Cruz Biotechnology), anti-phospho RNA
Pol II S2 (A300-654A, Betyl Laboratories), anti-CDK9 (C-20, Santa Cruz Bio-
technology), anti-MYC (06–340, Millipore), anti-a-Tubulin (T6199, Sigma) and
anti-b-actin (A-1978, Chemicon). To quantify protein expression ratios, immu-
noblots were assessed by ImageJ (v. 1.46r). The relative expression ratios of BCL-2,
BCL-XL, or MCL-1 to combined BCL-2, BCL-XL and MCL-1 were calculated using
the quantiﬁed intensity of each protein normalized against a-Tubulin. Co-immu-
noprecipitation was performed as described6 using the anti-HA (12CA5) or anti-
BCL-XL (7B2.5) antibodies and analysed by 10% NuPAGE (Life Technologies) and
immunoblots.
Xenograft studies. Animal experiments were performed in accordance with the
MSKCC Institutional Animal Care and Use Committee. Sex-matched 7–8 week-old
NOD/SCID/IL2Rgnull (NSG) mice (Jackson Laboratories) were injected sub-
cutaneously with 3 106 H446 cells in 0.2ml 50% Matrigel (BD Biosciences). The
PDX model (ECLC9) was derived from a patient previously treated with carbo-
platin and etoposide in accordance with the MSKCC Institutional Review Board
approved tissue collection protocol with informed consent from the patient and
propagated in NSG mice. Tumour growth was monitored twice weekly by calipers
(volume¼ lengthwidth2/2). When tumours reached B150mm3, tumour-bear-
ing mice were randomized according to tumour volume. ABT-199 (100mg kg 1)
was administered by oral gavage at a weekly schedule of 5 days on and 2 days off.
ABT-199 was formulated in 10% ethanol, 30% polyethylene glycol 400 and 60%
Phosal 50 PG. Doxorubicin was formulated in PBS and administered intravenously
once weekly at 2mg kg 1. Dinaciclib was formulated in 20% hydroxypropyl b-
cyclodextrin and administered intraperitoneally twice weekly at 20 or 30mg kg 1.
P-values for statistical analyses were obtained with two-way analysis of variance.
Data availability. All relevant data not presented in the main ﬁgures or
Supplementary Information is available from the corresponding author upon
request.
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